Reference number(s)
4228-D

This document applies to the following:

Formulary	Applies
Standard Control (SF)	☐
Standard Control – Choice (SCCF)	☐
Preferred Drug Plan Design (PDPD)	☐
Advanced Control Specialty (ACSF)	☐
Advanced Control Specialty – Choice (ACSCF)	☐
Managed Medicaid Template (MMT)	☑
Marketplace (MF)	☐
Aetna Small Group Affordable Care Act (SG ACA) Aetna Health Exchange (AHE)	☐
Aetna Individual Lives (IVL)	☐
Value (VF)	☐

Formulary	Applies
New to Market (NTM)	☐
Standard Formulary Chart (SFC)	☐
Basic Control Chart Preferred Drug Plan Design (BCC PDPD)	☐
Advanced Control Specialty Formulary Chart (ACSFC)	☐
Value Formulary Chart (VFC)	☐
Medical Benefit	☐
Medical Benefit: Advanced Biosimilars First	☐
Medical Benefit: Managed Medicaid (MMMB)	☐
Medicare Part B	☐
Medicare Part B: Advanced Biosimilars First	☐

Exceptions Criteria
Idiopathic Pulmonary Fibrosis (IPF)

This document informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

These criteria were developed to align with the following: Managed Medicaid Template (MMT).

Plan Design Summary

This program applies to the idiopathic pulmonary fibrosis (IPF) products specified in this document. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the preferred product and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to all members requesting treatment with Esbriet. This program applies to members who are new to treatment with Ofev for the first time.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. Idiopathic Pulmonary Fibrosis (IPF) Products

Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

	Product(s)
Preferred	• pirfenidone (generic)
Target	• Esbriet (pirfenidone) • Ofev (nintedanib)

Exception Criteria

This program applies to members requesting treatment for an indication that is FDA-approved for the preferred product.

Esbriet

Coverage for Esbriet is provided when the member has had a documented intolerable adverse event to the preferred product, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.

Ofev

Coverage for Ofev is provided when the member meets either of the following criteria:

- Member is currently receiving treatment with Ofev, excluding when Ofev is obtained as samples or via manufacturer's patient assistance programs.
- Member has a documented inadequate response or intolerable adverse event with the preferred product.

References

1. Esbriet [package insert]. South San Francisco, CA: Genentech, Inc.; February 2023.
2. Ofev [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; June 2024.
3. Pirfenidone [package insert]. Berkeley Heights, NJ: Laurus Generics Inc.; March 2023.

Document History

Created: Specialty Clinical Development (DG) 09/2020

Revised: AW 09/2021 (2022, no changes), AM 12/2021 (annual), JN 09/2022, CK 12/2022 (Annual), AR 09/2023 (2024), CNg 12/2023 (annual), CNg 09/2024 (2025)

Reviewed: CDPR/ ABM 10/2020, SAM 09/2021, CH 12/2021, APN 09/2022, DC 12/2022, AN 09/2023, APN 12/2023, APN 10/2024

External Review: 10/2020 (P&T subgroup), 02/2022, 02/2023, 02/2024

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.